Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + 5-fluorouracil + carvedilol

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination of four drugs: cyclophosphamide and doxorubicin (which are commonly used together as "AC" chemotherapy for breast cancer), 5-fluorouracil (another chemotherapy agent), and carvedilol (a beta-blocker typically used for cardiovascular conditions). While cyclophosphamide + doxorubicin is a standard chemotherapy combination, and sometimes 5-fluorouracil is used in cancer treatment protocols, the addition of carvedilol to this combination is unusual and not standard practice based on available information.

Targets

TS (Thymidylate synthase)ADRB1 (β1)ADRA1A (α1A)DNAADRB2 (β2)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + 5-fluorouracil + carvedilol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + 5-fluorouracil + carvedilol.

Explore the full profile